Gainers Senti Biosciences, Inc. (NASDAQ:SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Tharimmune, Inc. (NASDAQ:THAR) shares rose 76.8% to $0.2790 in pre-market trading as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104. TransMedics Group, Inc. (NASDAQ:TMDX) shares rose 39.7% to $56.16 in pre-market trading after the company reported better-than-expected third-quarter sales results and issued strong FY23 r

CF Acquisition Corp. IV (NASDAQ:CFIV) (the "Company") today announced that its special meeting in lieu of an annual meeting of the stockholders (the "Meeting") will be postponed from 10:00 a.m. to 4:00 p.m. Eastern Time on December 22, 2022. The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 17, 2022 (the "Record Date"). Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the Record Date can vote, even if they have subsequently sold their shares. Stockholders who wish to withdraw

  During Thursday's session, 108 stocks hit new 52-week highs. Interesting Facts About Today's 52-Week Lows: Eli Lilly (NYSE:LLY) was the largest company by market cap to set a new 52-week high. Limbach Holdings (NASDAQ:LMB) was the smallest company when considering market cap to set a new 52-week high. 4D Molecular Therapeutics (NASDAQ:FDMT)'s stock gained the most, trading up 10.47% to reach a new 52-week high. AES (NYSE:AES) shares suffered the most, as they hit a 52-week high but moved 0.0% down thereafter. The stocks that set new 52-week highs on Thursday are the following: Eli Lilly (NYSE:LLY) shares were up 0.18% for the day, having made a 52-week high of $375.19. Novo N

15-12G - CF ACQUISITION CORP. IV (0001825249) (Filer)

25-NSE - CF ACQUISITION CORP. IV (0001825249) (Subject)

8-K - CF ACQUISITION CORP. IV (0001825249) (Filer)

10-Q - CF ACQUISITION CORP. IV (0001825249) (Filer)

8-K - CF ACQUISITION CORP. IV (0001825249) (Filer)

10-Q - CF ACQUISITION CORP. IV (0001825249) (Filer)

8-K - CF ACQUISITION CORP. IV (0001825249) (Filer)

DEFA14A - CF ACQUISITION CORP. IV (0001825249) (Filer)

8-K - CF ACQUISITION CORP. IV (0001825249) (Filer)

DEF 14A - CF ACQUISITION CORP. IV (0001825249) (Filer)

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- CF Acquisition Corp. IV (NASDAQ:CFIV) ("CF IV"), a publicly traded special purpose acquisition company, today announced that its board of directors (the "Board") has determined to redeem all of its outstanding shares of Class A common stock, par value $0.0001 per share ("Class A common stock"), sold in its initial public offering (the "public shares") because CF IV is unlikely to be able to complete an initial business combination by the deadline under its Amended and Restated Certificate of Incorporation, as amended. Accordingly, CF IV

NEW YORK, June 7, 2023 /PRNewswire/ -- CF Acquisition Corp. IV (NASDAQ: CFIV) (the "Company") today announced that, to mitigate the current uncertainty surrounding the implementation of the Inflation Reduction Act of 2022, in the event that the extension (the "Extension") of the time period the Company has to complete an initial business combination (the "Business Combination") is implemented, as described in the proxy statement filed by the Company on May 22, 2023 (the "Proxy Statement"), in connection with its special meeting of stockholders to be held on June 22, 2023 (the "Meeting"), CFAC Holdings IV, LLC (the "Sponsor"), the sponsor of the Company, or a designee, will indemnify the Comp

NEW YORK, NY, Dec. 21, 2022 (GLOBE NEWSWIRE) -- CF Acquisition Corp. IV (NASDAQ:CFIV) (the "Company") today announced that its special meeting in lieu of an annual meeting of the stockholders (the "Meeting") will be postponed from 10:00 a.m. to 4:00 p.m. Eastern Time on December 22, 2022. The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 17, 2022 (the "Record Date"). Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the Record Date can vote, even if they have subsequently so